September 6, 2017 / 4:38 AM / 20 days ago

Swiss stocks - Factors to watch on Sept 6

ZURICH, Sept 6 (Reuters) - The Swiss blue-chip SMI was seen opening 0.1 percent easier at 8,864 points on Wednesday, according to premarket indications by bank Julius Baer.

Here are some of the main factors that may affect Swiss stocks:

CREDIT SUISSE

Chairman Urs Rohner called on regulators to clear the way for large cross-border mergers and acquisitions in the European banking industry, adding current rules make such transactions too difficult.

For more click

ROCHE

Patients taking Roche’s targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer’s Xalkori, new clinical trial data show. The results, which will be presented at the Sept. 8-12 European Society for Medical Oncology congress in Madrid, reinforce Alecensa’s position in an increasingly competitive market.

COMPANY STATEMENTS

* Straumann said it ‍generated CHF 260 million cash from sale of treasury shares to finance strategic acquisitions/investments; ‍shares were broadly placed with institutional investors at CHF 600 per share; company had said it aimed to place 432,665 of its own treasury shares, representing 2.7 percent of the company’s outstanding shares.

* Von Roll Holding AG says CFO Stephan Kellmann VON leaves group; Artur Lust succeeds him.

* Clariant announces a low-single-digit million franc investment to strengthen two of its North American Oil Services sites; investments upgrade facilities at the Midland, Texas and Clinton, Oklahoma sites and follow the acquisitions of Kel-Tech and X-Chem.

* Investis said it successfully placed a further fixed-rate bond with a volume of 180 million Swiss francs.

* Myriad said it has completed a rights issue, reaping proceeds of 18.7 million Swiss francs. Says directors purchased 195,000 shares at a price of CHF 0.50 per share.

* Julius Baer said it placed perpetual non-cumulative high-trigger additional tier 1 securities in a debut $300 million transaction, with an annual coupon of 4.75 percent.

* Novartis AG’s Novartis Pharma AG reports a 6.6 percent passive stake in Xoma Corp as of August 24, 2017 - SEC filing

* Swiss Estates AG announces delisting of convertible bond 2014

* EEII AG says H1 loss of CHF 0.88 mio (h1 2016: loss of CHF 0.95 mio.); major cause for disappointment was negative equity performance of Gazprom

* SGS announces acquisition of The Govmark Testing Services, Inc. (Govmark), an independent laboratory for fire resistance and reaction to fire testing. Privately owned Govmark employs 30 people and generated 2016 revenues in excess of $3 million.​‍​‍​

ECONOMY

Reporting by Zurich newsroom

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below